FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility

businesswire

FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility – NEWSnet – News… as it used to be

More Press Releases

May 30, 2026

AdvisorVault Adds Social Media Archiving to its Consolidated D3P Service

May 30, 2026

NUAI Deadline: NUAI Investors with Losses in Excess of $100K Have Opportunity to Lead New Era Energy & Digital, Inc. Securities Fraud Lawsuit

May 30, 2026

Tulsa’s Route 66 Capital Cruise Sets GUINNESS WORLD RECORDS™ Mark

May 30, 2026

FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility

AdvisorVault Adds Social Media Archiving to its Consolidated D3P Service

NUAI Deadline: NUAI Investors with Losses in Excess of $100K Have Opportunity to Lead New Era Energy & Digital, Inc. Securities Fraud Lawsuit

Tulsa’s Route 66 Capital Cruise Sets GUINNESS WORLD RECORDS™ Mark

TTW Unveils Top 50 Coolcation Travel Destinations in the World for 2026